Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Elan Sees Problems on Alzheimer's Drug; Puts Itself Up for Sale
- Elan, the troubled Irish pharma company, has put itself up for sale just as it emerged that it will spend another six months testing bapineuzumab, its experimental Alzheimer's treatment. The drug has previously been linked to brain swelling in some patients. The sale raises the possibility that Elan's bizarre managers...
- Blog posts 2009-01-14
- Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics
- Wyeth, Elan and Bapineuzumab -- How to Lie With Drug StatisticsRE: Wyeth, Elan and Bapineuzumab -- How to Lie With Drug StatisticsLook at page 15 at a dose of 0.15 mg/kg for APOE4 carriers and page 17 at a dose of 0.5 mg/kg for APOE4 noncarriers.http://library.corporate-ir.net/library/88/883/88326/items/302302/ELNWYE20080729.pdfThose a trualy amazing numbers.How...
- Discussion threads 2008-09-08
Additional Resources
- Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics
- In what is becoming a sadly common ritual, Wyeth and Elan are pressing forward with an expensive, large-scale "phase III" trial of a risky drug based on wishful thinking and shoddy statistical analysis. The drug in question is bapineuzumab, a monoclonal antibody intended to treat Alzheimer's disease...
- Blog posts 2008-07-29
- Elan Management Creates Self-Enrichment Plan as Pfizer-Wyeth Deal Threatens Bapineuzumab
- UPDATE: Elan says the share awards are part of "the normal annual compensation process" at Elan. See Elan's full statement in the comments section below. Elan's senior management have hatched a plan to enrich themselves in the event of a sale or takeover of their troubled...
- Blog posts 2009-02-17
- Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab in Alzheimer's Disease
- DUBLIN, Ireland & COLLEGEVILLE, Pa. -- Elan Corporation, plc (NYSE: ELN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the first patient in North America NA has been dosed as part of a global Phase 3 clinical program for bapineuzumab (AAB-001) in patients with mild to...
- Research articles 2007-12-21
- Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab in Alzheimer's Disease
- DUBLIN, Ireland & Madison, N.J. -- Elan Corporation, plc (NYSE: ELN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the decision to initiate a Phase 3 clinical program of their lead immunotherapeutic candidate, Bapineuzumab (AAB-001), for the treatment of patients with mild to moderate Alzheimer's Disease. This...
- Research articles 2007-05-21
- Wyeth Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. And we'll go to the line of Roopesh Patel of UBS. Please go ahead. Roopesh Patel - UBS Thank you. I've got a couple of questions. First on Pristiq in VMS, can you confirm that you are expecting a full...
- Earnings calls 2007-07-19
- Elan woes may open opportunities for Biogen, Wyeth
- By Toni Clarke - Analysis BOSTON (Reuters) - Elan Corp Plc's (ELN.I)(ELN.N) move to explore strategic options, including a sale or merger of the company, puts Biogen Idec Inc(BIIB.O) and Wyeth(WYE.N) in prime position to do a deal with the Irish drugmaker. That is, assuming Elan can get any deal...
- News items 2009-08-07
- Elan Silent on Corporate Jets as 230 Are Laid Off
- The 230 people being laid off by Elan Pharmaceuticals as part of its "further alignment of resources" and "on-going strategic review process" might want to ask whether Elan's three corporate jets are being laid off too. Elan's use of corporate jets is an issue for Jack Schuler,...
- Blog posts 2009-02-26
- Big Win for J&J with Elan Deal
- David Van Knapp submits: Johnson & Johnson JNJ has made a significant improvement to its business. Under a deal announced Thursday, J&J will take a major stake in biotech company Elan ELN, thereby gaining access to Elan's Alzheimer's disease treatments, in particular leading drug bapineuzumab. In the transaction, J&J...
- External links 2009-07-03
- J&J Comes Riding to Elan's Rescue
- EP Vantage submits: Johnson & Johnson has today taken what looks like a $1.5bn gamble on experimental drug bapineuzumab and the rest of Elan’s Alzheimer’s pipeline. In a surprising announcement, the US group revealed that it would be investing $1bn in exchange for an 18.4% stake in the Irish group...
- External links 2009-07-03
- How to Lose $100 Million in 40 Days
- The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...
- Blog posts 2008-07-01
- Elan Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. The first question comes from the line of Jack Gorman with Davy. Jack Gorman - Davy I just had a couple of questions on the final piece of information on the Phase 3 design that you shared with us, Lars, I suppose in the first...
- Earnings calls 2007-10-25
- Who Is the Worst Biotech CEO?
- Derek Lowe submits: I'm pleased to note that Adam Feuerstein over at TheStreet.com has announced his first-ever "Worst Biotech CEO" award. In what was surely a contested field, he's named Elan's ELN Kelly Martin as the winner. I was pulling for Ariad's ARIA Harvey Berger, who seems to have...
- External links 2008-12-14
- The Pfizer-Wyeth Deal Worst-Case Scenario
- UPDATE: The deal is done! Pfizer will get Wyeth for $68 billion. See BNET's look at the deal here. Meanwhile here's the pre-deal analysis: Folks are freaking out right now on CafePharma -- sample quote on the Wyeth board: "You're Pfucked!" What will the new company be...
- Blog posts 2009-01-23
- Pfizer's Wyeth Buy Eclipses $2.3 Bill. Bextra Troubles; 19,000 Layoffs to Come
- Today's announcement that Pfizer is to acquire Wyeth for $68 million eclipsed some things that on any other day would have been headline news in themselves: a) The fact that Pfizer's earnings were down 90 percent due to a $2.3 billion settlement with the Department of Justice over its off-label...
- Blog posts 2009-01-26
- If Novartis Buys Elan's Tysabri and MS Drug, There Won't Be Much Elan Left
- If Novartis was to buy the Tysabri and bapineuzumab parts of Elan, as suggested in this Reuters report via the Sunday Times, what, exactly, would be left? Just Prialt (revenues $3.8 million per quarter), Azactam, ($24.2 million) and Maxipime ($10.1 million). by Jim Edwards
- Blog posts 2009-06-28
- In Elan-J&J Deal, Many Unanswered Questions (Wyeth Being One)
- Johnson & Johnson's investment of $1 billion for an 18.34 percent stake in Elan raises more questions than answers. It promises to bring Elan's Alzheimer's candidate, bapineuzumab, to market but details of exactly how that will happen have yet to be revealed. by Jim Edwards
- Blog posts 2009-07-04
- Hoping Against Hope for Wyeth / Elan Alzheimer Dug
- Derek Lowe submits: Here's an interesting look at the current state of the Alzheimer's field from Bloomberg. The current big hope is Wyeth WYE (and Elan ELN)'s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the...
- External links 2009-07-21
- Wyeth Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you. Operator Instructions Your first question comes from Tim Anderson - Sanford Bernstein. Tim Anderson - Sanford Bernstein I have a single question for you, I guess, which is when we're going to learn the results of your go/no go decision for Phase III...
- Earnings calls 2009-07-23
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
